U.S. markets closed

Swedish Orphan Biovitrum AB (publ) (SOBI.ST)

Stockholm - Stockholm Real Time Price. Currency in SEK
219.10-0.40 (-0.18%)
At close: 05:29PM CET
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close219.50
Bid219.10 x 0
Ask219.30 x 0
Day's Range217.90 - 222.20
52 Week Range166.50 - 245.50
Avg. Volume387,311
Market Cap64.97B
Beta (5Y Monthly)0.39
PE Ratio (TTM)21.52
EPS (TTM)10.18
Earnings DateFeb 08, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est251.80
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for SOBI.ST

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • PR Newswire

      Bo Jesper Hansen proposed as new Chairman of the Board of Swedish Orphan Biovitrum AB (publ) ahead of the Annual General Meeting in 2023

      As previously communicated, Håkan Björklund, the current Chairman of the Board of Swedish Orphan Biovitrum AB (publ) (Sobi®), has announced that he will not be available for re-election at the company's Annual General Meeting in 2023. Sobi's Nomination committee proposes that the current Board member and Deputy Chairman Bo Jesper Hansen is elected as Chairman of the Board at the Annual General Meeting on 9 May 2023.

    • PR Newswire

      Sobi to present new data at the ASH 2022 Annual Meeting

      Sobi® will present new data at the 64th Annual Meeting of the American Society of Hematology (ASH) taking place from 10 to 13 December 2022. Sobi's commitment to developing innovative treatments for people living with rare diseases is highlighted in studies spanning several rare disorders, including haemophilia, paroxysmal nocturnal haemoglobinuria (PNH), cold agglutinin disease (CAD), immune thrombocytopenia (ITP) and primary haemophagocytic lymphohistiocytosis (pHLH).

    • PR Newswire

      Kineret® authorised for emergency use by FDA for the treatment of COVID-19 related pneumonia

      Sobi® today announced that the US Food and Drug Administration has granted Emergency Use Authorisation (EUA) for the use of Kineret® (anakinra) for the treatment of coronavirus disease 2019 (COVID-19) in hospitalised adults with pneumonia requiring supplemental oxygen (low- or high-flow oxygen) who are at risk of progressing to severe respiratory failure.